LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

The Business of Biotechnology: Growing for Europe’s tomorrow

15/02/2021
PRESS RELEASE

The Business of Biotechnology: Growing for Europe’s tomorrow
EuropaBio report ‘Measuring the Economic Footprint of the Biotechnology Industry in Europe’

European GDP benefitted by €38.5 bn in 2018, in the recent in-depth study from EuropaBio ‘Measuring the Economic Footprint of the Biotechnology Industry in Europe’. The study looked at the economic impact of the biotechnology industry within the (then) 28 European member states, in terms of gross value added (GVA), employment and trade. Including spill-over effects, that number rises to €78.7bn. The direct contribution adds up to about 1.5% of total industrial GVA within the countries assessed, supported by 223,000 direct jobs rising to over 900,000 with associated employment.

Looking to future economic development, biotechnology continues to mature as an economic force, with an average annual growth rate of 4.1% in 2018, twice as fast as Europe’s information and communication sector (2.0%) and the overall economy (1.9%), making it one of the fastest growing innovative industries in Europe. This reinforces its importance across sectors, both as an enabling technology with economic power in its own right, and also a transformative power for Europe’s future economic recovery and growth. Biotechnology also performed on the global stage for Europe in 2018, with a €22 bn trade surplus in high value goods, reflecting Europe’s innovative strength.

EuropaBio Director General Dr Claire Skentelbery commented “Biotechnology continues to demonstrate that it is a leading sector in European economic development. We don’t need to look far in 2021 to see how innovations are literally saving lives and, at EuropaBio, we also see how it is creating the solutions needed for Green Deal delivery”.

Andrew Topen Chair of the EuropaBio Board added “EuropaBio has been highlighting the significant economic and societal contribution from biotechnology for 25 years. This timely report demonstrates the vital importance of biotech and the importance of a strong ecosystem to foster innovation to the benefit of humanity.”

Join EuropaBio on March 4 at 14:00 CET for the webinar ‘Measuring the Economic Footprint of the Biotechnology Industry in Europe: Landscape and Positions for Development’ where we discuss the report and implications for future economic performance for biotechnology across sectors. About ‘Measuring the Economic Footprint of the Biotechnology Industry in Europe’.

This economic impact study was conducted by WifOR Institute – an independent research institute specialising in impact analysis – in association with the European Association of Bioindustries, EuropaBio. Direct, indirect, and induced effects generated by the biotechnology industry in the EU28 are quantified in accordance with the system of national accounts and using a multiregional input-output model.

Download the full PRESS RELEASE below.

The Business of Biotechnology: Growing for Europe’s tomorrow


Download
2021_02_G_PRESS-RELEASE_EuropaBio_WifOR_The-Economic-Impact-of-BiotechnologyDownload
Share
Alexandra Simionca
Alexandra Simionca

Related posts

07/07/2025

EuropaBio Position on the Critical Medicines Act


Read more
03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more
26/06/2025

EuropaBio AGM 2025: Association Chair, Executive Committee and Board announced


Read more

Important links

  • EuropaBio Position on the Critical Medicines Act
  • Life Sciences Strategy Embraces Biotech for Global Impact

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.